Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen).

East, Cara; Bass, Kyle; Mehta, Ankit; Rahimighazikalayed, Gelareh; Zurawski, Sandy; Bottiglieri, Teodoro

East, Cara; Bass, Kyle; Mehta, Ankit; Rahimighazikalayed, Gelareh; Zurawski, Sandy; Bottiglieri, Teodoro.

East C; Baylor Soltero CV Research Center, Baylor Scott & White Research Institute, Dallas, Texas.
Bass K; Baylor Scott & White Research Institute, Baylor Scott & White Research Institute, Dallas, Texas.
Mehta A; Baylor Heart & Vascular Hospital, Baylor Scott & White Research Institute, Dallas, Texas.
Rahimighazikalayed G; Baylor Soltero CV Research Center, Baylor Scott & White Research Institute, Dallas, Texas.
Zurawski S; Baylor Scott & White Research Institute, Baylor Scott & White Research Institute, Dallas, Texas.
Bottiglieri T; Baylor University Medical Center, Baylor Scott & White Research Institute, Dallas, Texas.

Kidney Med ; 4(7): 100483, 2022 Jul.

Article en En | MEDLINE | ID: mdl-35801187